Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT3214 in Adults With Advanced Solid Tumors
NCT07455734Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Mar 2026
- Primary completion
- Oct 2030
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of BNT3214 in solid tumor (advanced stage) (4 arms), sponsored by BioNTech SE. Primary endpoints: Treatment Emergent Adverse Events, Dose interruptions, reductions, and discontinuation due to TEAEs at 24 months and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
BNT3214
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07455734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455734.